Estudos

http://aformulabr.com.br/qrcode/biointestilafv01.pdf
 BIOINTESTIL®
Eficácia garantida na Síndrome do Intestino Irritável

DESCRIÇÃO
O BIOintestil® é constituído por uma associação de componentes naturais, o óleo essencial da Cymbopogon martinii
(Roxb.) Wats (padronizado em geraniol) e a fibra do rizoma de Zingiber officinale (padronizado em 6-gingerol),
produzido através de processo tecnológico patenteado.

MECANISMO DE AÇÃO
BIOintestil® através de sua tecnologia inovadora permite que a fibra se ligue às moléculas lipofílicas como colesterol
e sais biliares, impedindo a sua absorção no estômago e intestino delgado, tendo ação exclusiva no cólon sendo
naturalmente degradada pela microbiota intestinal. Os componentes de BIOintestil® demonstram uma notável
atividade moduladora da microbiota, regularizando o canal intestinal tanto em pacientes com Síndrome do Intestino
Irritável do tipo diarreico, quanto em pacientes com Síndrome do Intestino Irritável do tipo mista e constipativa.
BIOintestil® apresenta ainda propriedades anti-inflamatórias através do geraniol que atua como inibidor da COX-2,
com consequente redução dos níveis de mediadores inflamatórios; e atividade antimicrobiana seletiva, ligando-se à
parede bacteriana, modificando sua organização dinâmica, a exemplo da perda de íons e depleção de ATP. Através
do rizoma do gengibre, o BIOintestil® possui ação antiemética, com a capacidade de regularizar a mobilidade
gastrointestinal, inclusive na eliminação de gases.

INDICAÇÕES
 Aumento da motilidade intestinal; Equilíbrio da microbiota intestinal;
 Gases, náuseas e vômitos;
 Síndrome do Intestino Irritável;
 Inchaço e dores abdominais.

DOSE USUAL
Recomendação oral de 600 a 1800mg BIOintestil® (óleo essencial de C. martinii + fibra de Z. officinale) ao dia.

SUGESTÕES DE FÓRMULAS
BIOintestil® (óleo essencial de C. martinii + fibra de Z.
officinale)........……..............….…………...………600mg
Modo de uso: 1 dose, 2 vezes ao dia, antes das
principais refeições, por um período de 4 a 6
semanas.
Indicação: síndrome do intestino irritável e equilíbrio
da flora intestinal.
BIOintestil® (óleo essencial de C. martinii + fibra de Z.
officinale)........……..............….…………...………600mg
Relora® (P. amurense,M. officinalis)........................ 250mg
Modo de uso: 1 dose, 2 vezes ao dia.
Indicação: equilíbrio da flora intestinal.
BIOintestil® (óleo essencial de C. martinii + fibra de Z.
officinale)........……..............….…………...………600mg
Peumus boldus ext seco...................................250mg

Modo de uso: 1 dose, 2 vezes ao dia.

Indicação: saúde intestinal; desconforto e dores
abdominais.
PRINCIPAIS REFERÊNCIAS

ONAWUNMI, Grace O.; YISAK, Wolde-Ab; OGUNLANA, E. O. Antibacterial constituents in the essential oil of Cymbopogon citratus (DC.) Stapf. Journal of
Ethnopharmacology, v. 12, n. 3, p. 279-286, 1984. Disponível em: < https://www.ncbi.nlm.nih.gov/pubmed/6442749> Acesso em 19/07/2017 às 15:10.

THOMSON, M. et al. The use of ginger (Zingiber officinale Rosc.) as a potential anti-inflammatory and antithrombotic agent. Prostaglandins, leukotrienes
and essential fatty acids, v. 67, n. 6, p. 475-478, 2002. Disponível em: < https://www.ncbi.nlm.nih.gov/pubmed/12468270> Acesso em 19/07/2017 às 15:00.
 BIOINTESTIL®
ESTUDOS CLÍNICOS
Ensaio clínico em pacientes com Síndrome do Intestino Irritável
A disbiose é caracterizada por desequilíbrio na microbiota intestinal e
é uma das causas do desenvolvimento da Síndrome do Intestino
Irritável. Em pessoas saudáveis adultas, a microbiota deve ter uma
proporção entre bacteroidetes e firmicutes de 1:1.
MÉTODOS: Nos pacientes analisados com sintomatologia mista (SII-
M) ou diarréicas (SII-D), no início do estudo, a microbiota intestinal
apresentou-se, em média, caracterizada por bacteroidetes
excessivas, particularmente acentuada em SII-D.
RESULTADOS: O tratamento com BIOintestil®, reduziu
significantemente o excesso de bacteroidetes no tempo T2, e essa
redução foi mantida também no tempo T3 em pacientes com
diagnóstico de SII-M.No grupo com sintomatologia constipativa (SII-
C) o tratamento com o BIOintestil® tem como efeito no tempo T2 um
forte reequilíbrio da microbiota intestinal, seja em termos de
biodiversidade quanto em termos de relação bacteroidetes-firmicutes

Score da doença foi analisado através do teste de IBS-

VAS (Escala Analógica Visual para a Síndrome do
Intestino Irritável) amplamente validado em clínica. Os
resultados mostrados na Figura 2 indicam uma redução
significativa (p<0,05) do score no tempo T2, e que em
diversos pacientes ficaram mantidos também no tempo
T3 (pausa).

Inhibition of prostaglandin and leukotriene biosynthesis by gingerols and diarylheptanoids

The rhizomes of Zingiber officinale (ginger) and Alpinia officinarum contain potent inhibitors against prostaglandin
biosynthesizing enzyme (PG synthetase). Gingerols and diarylhepatanoids were identified as active compounds. Their
possible mechanism of action which was deduced from the structures of active compounds indicated that the inhibitors
would also be active against arachidonate 5-lipoxygenase, an enzyme of leukotriene (LT) biosynthesis. This was verified
by testing their inhibitory effects on 5-lipoxygenase prepared from RBL-1 cells. A diarylheptanoid with catechol group
was the most active compound against 5-lipoxygenase, while yakuchinone A was the most active against PG
synthetase.
Sensitivity of pathogenic and commensal bacteria from the human colon to essential oils

The microbiota of the intestinal tract plays an important role in colonic health, mediating many effects of dietary
components on colonic health and during enteric infections. In the context of the increasing incidence of antibiotic
resistance in gut bacteria, complementary therapies are required for the prevention and treatment of enteric infections.
Here we report the potential application of essential oils (EO) and pure EO compounds to improve human gut health.
Nerolidol, thymol, eugenol and geraniol inhibited growth of the pathogens Escherichia coli O157 : H7(VT(-)), Clostridium
difficile DSM1296, Clostridium perfringens DSM11780, Salmonella typhimurium 3530 and Salmonella enteritidis S1400
at a half-maximal inhibitory concentration (IC(50)) varying from 50 to 500 p.p.m. Most EO showed greater toxicity to
pathogens than to commensals. However, the beneficial commensal Faecalibacterium prausnitzii was sensitive to EO
at similar or even lower concentrations than the pathogens. The EO showed dose-dependent effects on cell integrity,
as measured using propidium iodide, of Gram-positive bacteria. These effects were not strongly correlated with growth
inhibition, however, suggesting that cell membrane damage occurred but was not the primary cause of growth inhibition.
Growth inhibition of Gram-negative bacteria, in contrast, occurred mostly without cell integrity loss. Principal component
analysis showed clustering of responses according to bacterial species rather than to the identity of the EO, with the
exception that responses to thymol and nerolidol clustered away from the other EO. In conclusion, the selective effects
of some EO might have beneficial effects on gut health if chosen carefully for effectiveness against different species.

The Effectiveness of Ginger in the Prevention of Nausea and Vomiting during Pregnancy and Chemotherapy

The rhizomes of Zingiber officinale (ginger) have been used since ancient times as a traditional remedy for
gastrointestinal complaints. The most active ingredients in ginger are the pungent principles, particularly gingerols and
shogaols. Various preclinical and clinical studies have evaluated ginger as an effective and safe treatment for nausea
and vomiting in the context of pregnancy and as an adjuvant treatment for chemotherapy-induced nausea and vomiting.
Here, we provide an update and analysis of ginger use for the prevention of nausea and vomiting, with a focus on the
types and presentations of ginger available. We also examine the pharmacokinetic properties of ginger and highlight
the type and posology of ginger and its metabolites.

The use of ginger (Zingiber officinale Rosc.) as a potential anti-inflammatory and antithrombotic agent.

The effect of an aqueous extract of ginger (Zingiber officinale) on serum cholesterol and triglyceride levels as well as
platelet thromboxane-B(2) and prostaglandin-E(2) production was examined. A raw aqueous extract of ginger was
administered daily for a period of 4 weeks, either orally or intraperitoneally (IP) to rats. Fasting blood serum was
investigated for thromboxane-B(2), prostaglandin-E(2), cholesterol and triglycerides. A low dose of ginger (50 mg/kg)
administered either orally or IP did not produce any significant reduction in the serum thromboxane-B(2) levels when
compared to saline-treated animals. However, ginger administered orally caused significant changes in the serum
PGE(2) at this dose. High doses of ginger (500 mg/kg) were significantly effective in lowering serum PGE(2) when given
either orally or IP. However, TXB(2) levels were significantly lower in rats given 500 mg/kg ginger orally but not IP. A
significant reduction in serum cholesterol was observed when a higher dose of ginger (500 mg/kg) was administered.
At a low dose of ginger (50 mg/kg), a significant reduction in the serum cholesterol was observed only when ginger was
administered IP. No significant changes in serum triglyceride levels were observed upon administration of either the low
or high dose of ginger. These results suggest that ginger could be used as an cholesterol-lowering, antithrombotic and
anti-inflammatory agent.

Geraniol inhibits murine skin tumorigenesis by modulating COX-2 expression, Ras-ERK1/2 signaling pathway
and apoptosis

Geraniol (GOH), a naturally occurring monoterpene, has been shown to have antiproliferative, cell cycle arrest and
apoptosis-inducing effects, and represents a promising cancer chemopreventive agent. In the present study, we
investigated the chemopreventive potential of GOH (50 and 100 mg kg(-1) body weight) against 7,12-
dimethylbenz[a]anthracene (DMBA)/12-O-tetradecanoylphorbol 13-acetate (TPA)-mediated skin tumorigenesis in
Swiss albino mice. The topical treatment of GOH, 30 min prior to TPA (2 µg per 200 µl of acetone) treatment significantly
inhibited TPA-induced skin edema, hyperplasia, COX-2 induction and oxidative stress response. The GOH treatment
also resulted in reduction of TPA-induced ornithine decarboxylase activity and [(3) H] thymidine incorporation by 53%
(P < 0.001) and 41% (P < 0.001), respectively. We found that GOH treatment significantly inhibited the tumor incidence
and number of tumors (P < 0.001) and extended the latency period from 4 weeks in DMBA/TPA treatment group to
10 weeks in GOH-pretreated mice. Furthermore, we observed that GOH treatment significantly suppressed the
Ras/Raf/ERK1/2 signaling pathway in skin tumor. Consistently, GOH-treated skin tumors showed reduced expression
of Bcl-2 and increased expression of Bax in these lesions. Thus, it was concluded that GOH inhibits DMBA/TPA-
mediated skin tumorigenesis by attenuating the Ras proliferation pathway and inducing pro-apoptotic state via inhibition
of oxidative stress response and inflammation.

Geraniol rescues inflammation in cellular and animal models of mevalonate kinase deficiency

BACKGROUND/AIM: The inhibition of the mevalonate pathway through genetic defects such as mevalonate kinase
deficiency (MKD) or pharmacological drugs such as aminobisphosphonates causes a shortage of intermediate
compounds, in particular geranylgeranyl-pyrophosphate (GGPP), which is associated with the consequent augmented
IL-1β release in monocytes. Considering that, due to its biochemical structure, isoprenoid geraniol enters the
mevalonate pathway and may revert the genetic or pharmacological inhibition, the present study tested isoprenoid
geraniol in cellular and animal MKD models obtained through the use of aminobisphosphonate pamidronate.
MATERIALS AND METHODS: The effect of natural isoprenoid geraniol on bacterial induced-inflammation was
evaluated in a monocytic cell line (Raw 264.7) and in Balb/c mice treated with pamidronate. RESULTS: Geraniol
diminished the levels of inflammatory markers induced by pamidronate stimuli in vitro and in vivo. CONCLUSION:
Geraniol may be proposed as a novel therapeutic approach for the orphan disease MKD, and may also be considered
for the evaluation of possible inflammatory side-effects of aminobisphosphonates.

Antibacterial constituents in the essential oil of Cymbopogon citratus (DC.) Stapf.

Cymbopogon citratus (DC.) Stapf. commonly known as lemon grass and used, over many years, for medicinal purposes
in West Africa, produces a volatile oil on steam extraction of its leaves. The antibacterial properties of the essential oil
have been studied. These activities are shown in two of the three main components of the oil identified through
chromatographic and mass spectrometric methods. While the alpha-citral (geranial) and beta-citral (neral) components
individually elicit antibacterial action on gram-negative and gram-positive organisms, the third component, myrcene, did
not show observable antibacterial activity on its own. However, myrcene provided enhanced activities when mixed with
either of the other two main components identified.

REFERÊNCIAS
KIUCHI, Fumiyuki et al. Inhibition of prostaglandin and leukotriene biosynthesis by gingerols and diarylheptanoids. Chemical and Pharmaceutical
Bulletin, v. 40, n. 2, p. 387-391, 1992. Disponível em: < https://www.ncbi.nlm.nih.gov/pubmed/1606634> Acesso em 19/07/2017 às 14:50.

THAPA, Dinesh et al. Sensitivity of pathogenic and commensal bacteria from the human colon to essential oils. Microbiology, v. 158, n. 11, p. 2870-
2877, 2012. Disponível em: < https://www.ncbi.nlm.nih.gov/pubmed/22878397> Acesso em 19/07/2017 às 15:00.

THOMSON, M. et al. The use of ginger (Zingiber officinale Rosc.) as a potential anti-inflammatory and antithrombotic agent. Prostaglandins,
leukotrienes and essential fatty acids, v. 67, n. 6, p. 475-478, 2002. Disponível em: < https://www.ncbi.nlm.nih.gov/pubmed/12468270> Acesso
em 19/07/2017 às 15:00.

LETE, Iñaki; ALLUÉ, José. The effectiveness of ginger in the prevention of nausea and vomiting during pregnancy and chemotherapy. Integrative
medicine insights, v. 11, p. 11, 2016. Disponível em: < https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818021/> Acesso em 19/07/2017 às 15:00

CHAUDHARY, Sandeep Chand et al. Geraniol inhibits murine skin tumorigenesis by modulating COX‐2 expression, Ras‐ERK1/2 signaling pathway
and apoptosis. Journal of Applied Toxicology, v. 33, n. 8, p. 828-837, 2013. Disponível em: <
https://www.ncbi.nlm.nih.gov/labs/articles/22760862/> Acesso em 19/07/2017 às 15:15.

MARCUZZI, Annalisa; CROVELLA, Sergio; PONTILLO, Alessandra. Geraniol rescues inflammation in cellular and animal models of mevalonate
kinase deficiency. In vivo, v. 25, n. 1, p. 87-92, 2011. Disponível em: < https://www.ncbi.nlm.nih.gov/pubmed/21282739> Acesso em 19/07/2017 às
15:20

ONAWUNMI, Grace O.; YISAK, Wolde-Ab; OGUNLANA, E. O. Antibacterial constituents in the essential oil of Cymbopogon citratus (DC.)
Stapf. Journal of Ethnopharmacology, v. 12, n. 3, p. 279-286, 1984. Disponível em: < https://www.ncbi.nlm.nih.gov/pubmed/6442749> Acesso
em 19/07/2017 às 15:10.

“Literatura do fornecedor”